Anna Piekarska

ORCID: 0000-0002-7188-4881
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19
  • HIV/AIDS drug development and treatment
  • Systemic Lupus Erythematosus Research
  • Liver Disease and Transplantation
  • HIV/AIDS Research and Interventions
  • Genomics, phytochemicals, and oxidative stress
  • Liver Diseases and Immunity
  • HIV Research and Treatment
  • MicroRNA in disease regulation
  • HIV-related health complications and treatments
  • Polish Law and Legal System
  • Viral Infections and Immunology Research
  • Phytochemicals and Antioxidant Activities
  • COVID-19 epidemiological studies
  • Chronic Lymphocytic Leukemia Research
  • Free Radicals and Antioxidants
  • COVID-19 and healthcare impacts
  • Animal Virus Infections Studies
  • Agriculture, Plant Science, Crop Management
  • Bullying, Victimization, and Aggression

Medical University of Lodz
2016-2025

University of Siena
2021

Medical University of Warsaw
2019-2020

Pomeranian Medical University
2005-2020

Medical University of Lublin
2020

Wroclaw Medical University
2020

University of Wrocław
2020

Medical University of Białystok
2017-2020

Nicolaus Copernicus University
2020

Collegium Medicum in Bydgoszcz
2020

Virologic and safety outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ribavirin (OBV/PTV/r DSV RBV) therapy have shown high sustained virologic response (SVR) rates good tolerability in most patient populations pre-registration studies.To confirm these clinical trial findings the treatment genotype 1 4 hepatitis C under real-world conditions.Patients enrolled for with OBV/PTV/r RBV based on therapeutic guidelines were included, regimen was administered according to product...

10.1111/apt.13790 article EN Alimentary Pharmacology & Therapeutics 2016-09-09

10.1016/s2352-3018(17)30179-0 article EN The Lancet HIV 2017-10-12

In this study, different Polish cultivars of blue-berried honeysuckles (Lonicera caerulea L.), wild and bog bilberry, were analyzed for bioactive compounds. The chemical properties verified included composition anthocyanins other polyphenols, antioxidant activity, profiles antioxidants by HPLC postcolumn derivatization or TLC. activities honeysuckle similar to that wild-growing bilberries (ranging from 170 417 μmol TE/g dm in ABTS 93 166 DPPH Folin-Ciocalteu tests). major anthocyanin the was...

10.1021/jf2039839 article EN Journal of Agricultural and Food Chemistry 2012-01-23

symptoms, the signs of acute respiratory failure develop, which leads to multiorgan and death patient.Mortality rates ranging from 0% 8% vary country depend on quality health care, in particular equipment availability intensive care units, but perhaps also many unknown human genetic factors / or virus mutability.Etiotropic treatment confirmed clinical trials is not available.There are attempts use drugs registered so far for other indications, their effectiveness has been either.Work...

10.20452/pamw.15270 article EN Polskie Archiwum Medycyny Wewnętrznej 2020-03-31

Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease inflammatory response and control symptoms severe coronavirus disease 2019 (COVID-19), but evidence is scarce.This retrospective study included patients with COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes clinical status markers.Twenty-eight were (19 male), a mean age 61.7 ± 12.4 years. The time from symptom onset to first dose was 10.5 5.7 days....

10.1080/14787210.2020.1800453 article EN Expert Review of Anti-infective Therapy 2020-07-22

The first Polish recommendations regarding the management of patients with COVID-19 were published by Society Epidemiologists and Infectiologists (PTEiLChZ) on March 31, 2020, last annex was dated November 12, 2021. ongoing state pandemic, emergence new variants virus, availability drugs necessitate their updating. Changes introduced in current version for comprised possibility using remedesivir an outpatient setting, previously reserved inpatient treatment, as well other antiviral...

10.20452/pamw.16230 article EN Polskie Archiwum Medycyny Wewnętrznej 2022-03-30

This study aimed to compare the clinical picture of COVID-19 in initial and later period Omicron dominance identify populations still at risk. A retrospective comparison data 965 patients hospitalized during early Omicron's (EO, January-June 2022) with 897 from a (LO, July 2022-April 2023) SARSTer database was performed. Patients LO, compared EO, were older, had better condition on admission, lower need for oxygen mechanical ventilation, less frequent lung involvement imaging, showed much...

10.3390/jcm12175572 article EN Journal of Clinical Medicine 2023-08-26

The relationship between the ability to accumulate heavy metals (represented by Cd and Zn) synthesize bioactive compounds glucosinolates [GLS]) was investigated in two cabbage cultivars. Plants were grown greenhouse of a phytotron under controlled conditions soils spiked with different Zn or concentrations. measurements contents soil (leaf) samples performed atomic absorption spectroscopy, whereas GLS levels determined high-performance liquid chromatography. ranges metal 80 450 mg/kg dry...

10.1002/etc.1977 article EN Environmental Toxicology and Chemistry 2012-08-08

Air pollution can adversely affect the immune response and increase severity of viral disease. The present study aimed to explore relationship between symptomatology, clinical course, inflammation markers adult patients with coronavirus disease 2019 (COVID-19) hospitalized in Poland (n = 4432) air levels, i.e., mean 24 h max level benzo(a)pyrene (B(a)P) particulate matter <10 μm (PM10) <2.5 (PM2.5) during a week before their hospitalization. Exposures PM2.5 B(a)P exceeding limits were...

10.1016/j.envpol.2022.119469 article EN cc-by-nc-nd Environmental Pollution 2022-05-14
Joseph J. Eron Chloe Orkin Douglas Cunningham Federico Pulido Frank A. Post and 95 more Christoph Stephan Erkki Lathouwers Veerle Hufkens John Jezorwski Romana Petrovic Kimberley Brown Erika Van Landuyt Magda Opsomer Christoph Stephan Éric Florence Michel Moutschen Eric Van Wijngaerden Linos Vandekerckhove Bernard E. Van Beers Jason Brunetta Brian Conway Marina B. Klein Daniel Murphy Anita Rachlis Stephen D. Shafran Sharon Walmsley F. Ajana Laurent Cotte P.-M. Girardy Christine Katlama Jean‐Michel Molina Isabelle Poizot‐Martin François Raffi D. Rey Jacques Reynes Elina Teicher Yazdan Yazdanpanah Jacek Gąsiorowski Waldemar Halota Andrzéj Horban Anna Piekarska Anita Witor José Ramón Arribas Ignacio Valero Juan Berenguer José L. Casado José M. Gatell Félix Gutiérrez Marı́a José Galindo María del Mar Gutiérrez José Antonio Iribarren Hernando Knobel Eugènia Negredo Juan A. Pineda Daniel Podzamczer Joaquín Portilla Federico Pulido C Ricart Antonio Rivero I Santos Gil Anders Blaxhult Leo Flamholc Magnus Gisslén Anders Thalme Jan Fehr Andri Rauch Marcel Stoeckle Amanda Clarke B Gazzard Mikayla Johnson Chloe Orkin Frank A. Post Andrew Ustianowski Laura Waters Joseph I. Bailey Paul Benson Laveeza Bhatti Indira Brar U. Fritz Bredeek Cynthia Brinson Gordon Crofoot Douglas Cunningham E DeJesus Craig Dietz Robin Dretler Joseph J. Eron Franco Felizarta Carl J. Fichtenbaum Joel E. Gallant Joseph Gathe Debbie Hagins S Henn W. Keith Henry Gregory Huhn Mamta K. Jain Christopher Lucasti Claudia Martorell Cheryl McDonald Anthony Mills Javier O Morales-Ramirez

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants the PI arm offered switch (late-switch, 44 exposure). All...

10.1016/j.antiviral.2019.104543 article EN cc-by-nc-nd Antiviral Research 2019-07-04

Long-term analyses of demographical and clinical characteristics COVID-19 patients can provide a better overview the course disease. They also help understand whether changes in infection symptomatology, disease severity, outcome occur over time. We aimed to analyze demographics, early symptoms infection, laboratory parameters, manifestation hospitalized during first 17 months pandemic Poland (March 2020–June 2021). The patients’ data (n = 5199) were extracted from national SARSTer database...

10.3390/jcm11010117 article EN Journal of Clinical Medicine 2021-12-26

The emergence of a highly transmissible and more pathogenic B.1.617.2 (delta) variant SARS-CoV-2 has brought concern over COVID-19 vaccine efficacy the increased risk severe breakthrough infections. objective this study was to assess frequency clinical characteristics cases recorded in 10 Polish healthcare units between 1 June 31 December 2021, period during which rapid surge share infections seen, while significant number populations were already fully vaccinated. Overall, 723 individuals...

10.3390/vaccines10040557 article EN cc-by Vaccines 2022-04-04

Nearly 290000 patients with chronic hepatitis C die annually from the most severe complications of disease. One them is liver cirrhosis, which occurs in about 20% chronically infected virus (HCV). Direct-acting antivirals (DAAs), replaced interferon (IFN)-based regimens, significantly improved prognosis this group patients, increasing HCV eradication rates and tolerability therapy. Our study first to assess changes patient profile, effectiveness, safety HCV-infected cirrhotic population...

10.3748/wjg.v29.i13.2015 article EN cc-by-nc World Journal of Gastroenterology 2023-03-30
Coming Soon ...